US Stock MarketDetailed Quotes

OTLK Outlook Therapeutics

Watchlist
  • 1.380
  • -0.120-8.00%
Close Feb 27 16:00 ET
  • 1.410
  • +0.030+2.17%
Post 16:32 ET
44.18MMarket Cap-0.56P/E (TTM)

About Outlook Therapeutics Company

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Company Profile

SymbolOTLK
Company NameOutlook Therapeutics
Listing DateJun 13, 2016
Founded2010
CEOMr. Lawrence A. Kenyon
MarketNASDAQ
Employees23
Fiscal Year Ends09-30
Address111 South Wood Avenue,Unit 100
CityIselin
ProvinceNew Jersey
CountryUnited States of America
Zip Code08830
Phone1-609-619-3990
Websitehttp://www.outlooktherapeutics.com

Company Executives

  • Name
  • Position
  • Salary
  • Lawrence A. Kenyon
  • Interim Chief Executive Officer, Chief Financial Officer, Executive Vice President, Treasurer, Secretary, Principal Accounting Officer and Director
  • 634.60K
  • Jeff Evanson
  • Chief Commercial Officer
  • 768.03K
  • Faisal G. Sukhtian
  • Chairman of the Board
  • 113.00K
  • Kurt J. Hilzinger
  • Independent Director
  • 95.00K
  • Dr. Julia A. Haller, M.D.
  • Independent Director
  • 79.00K
  • Andong Huang
  • Independent Director
  • 75.00K
  • Dr. Gerd U. Auffarth, M.D.
  • Independent Director
  • 79.00K
  • Yezan Munther Haddadin
  • Independent Director
  • 110.00K
  • Ralph H. Thurman
  • Lead Independent Director
  • 242.50K
  • Julian S. Gangolli
  • Independent Director
  • 112.50K

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
WANDA BEARING
920002
+30.00%
HENDERA
831152
+29.97%
LINGOOD
833284
+29.95%
4
WUHAN LAND
830779
+25.43%
5
TECHVISION
832876
+21.28%
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Monetary Policy: Navigating the Fed's Rate Cut Cycle
Changing Fed policy is altering the market math for investors.
Discussing
Tesla's earnings caused fluctuations, what's your market outlook？
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More
TSLA earnings preview: Grab rewards by guessing the opening price!